A Plain Language Summary of Quality of Life with Sacituzumab Govitecan Treatment in the TROPiCS-02 Study in Participants with Breast Cancer (HR-Positive/HER2-Negative)
March 2025
in “
Future Oncology
”
TLDR Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
The TROPiCS-02 study evaluated the effectiveness of sacituzumab govitecan in 776 participants with HR-positive/HER2-negative advanced or metastatic breast cancer. Results showed that those treated with sacituzumab govitecan lived longer and had a longer duration before cancer progression compared to standard chemotherapy. Participants also reported a better overall quality of life, including improved physical functioning and less shortness of breath, although they experienced more diarrhea and hair loss. These findings suggest that sacituzumab govitecan may be a beneficial treatment option for maintaining well-being and daily functioning in this patient population.
